glp 1 receptor drugs Frontiers List of approved and pending

doi: 10.1038/nrgastro.2016.181 14 SodhiMRezaeianzadehRKezouhAEtminanM

This landscape features major pharmaceutical companies developing GLP-1 therapies, service providers supporting clinical trials, regulatory agencies overseeing safety and efficacy, and end users such as hospitals, clinics, and home care settings

Why are investors betting on combination therapies like CagriSema over single-drug approaches

Tirzepatide (Mounjaro) Tirzepatide is unique because it targets two hormones: GLP-1 and glucose-dependent insulinotropic polypeptide (GIP)

Its physiological actions include stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon release, slowing gastric emptying, and promoting satiety through central nervous system pathways